What IL-17 Inhibitor can do for your PsA and AxSpA Patients

Introduction

Take This Event

Despite the availability of treat-to-target strategies, many psoriatic arthritis (PsA) patients are undertreated. Tight control across multiple domains of PsA improves clinical outcomes and QoL. Axial spondyloarthritis (axSpA) refers to the inflammation of the axial skeleton and encompasses two subtypes of the same disease: AS/r-axSpA and nr-axSpA. Lack of effective alternative therapies in axSpA leads to inadequate response or failure to maintain response.

Objectives

To provide information on the role of IL-17 inhibition in the treatment of AS/r-axSpA. Physicians will share their experiences through real life cases on the role of IL-17 inhibition in PsA management.

See Registration Policies, Cancellations & Refunds